SEARCH

SEARCH BY CITATION

References

  • 1
    McGuire D, Granger C. Diabetes and ischemic heart disease. Am Heart J. 1999;138:S366S375.
  • 2
    Vinik A, Ullal J, Parson H, et al. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab. 2006;2:269281.
  • 3
    Gall M, Hougaard P, Borch-Johnsen K, et al. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314:783788.
  • 4
    Association AD. Standards of Medical Care in Diabetes-2011. Diabetes Care. 2011;34:S11S61.
  • 5
    Blaj S, Stanciu S, Jurcut C, et al. Hypertension in obese patients: a dysmetabolic hypertension with a possible adipocyte dysfunction mechanism. Rom J Intern Med. 2003;41:103111.
  • 6
    Izzo R, de Simone G, Chinali M, et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009;32(5):845850.
  • 7
    Bakhai A. Adipokines – targeting a root cause of cardiometabolic risk. QJM. 2008;101:767776.
  • 8
    Kershaw E, Flier J. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:25482556.
  • 9
    Mathieu P, Poirier P, Pibarot P, et al. Visceral obesity: the link among inflammation, hypertension, and cardiovascular disease. Hypertension. 2009;53:577584.
  • 10
    Achard V, Boullu-Ciocca S, Desbriere R, et al. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol. 2007;292:R274R282.
  • 11
    Sowers J. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597H1602.
  • 12
    Leung KK, Leung PS. Effects of hyperglycemia on angiotensin II receptor type 1 expression and insulin secretion in an INS-1E pancreatic beta-cell line. JOP. 2008;9(3):290299.
  • 13
    Jonsson J, Clouston A, Ando Y, et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121:148155.
  • 14
    Weir M, Dzau V. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999;12:205S213S.
  • 15
    Hitomi H, Kiyomoto H, Nishiyama A, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007;50:750755.
  • 16
    Krug A, Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertens Pregnancy. 2008;51:12521258.
  • 17
    Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101(9):975980.
  • 18
    McGuire D, Winterfield J, Rytlewski J, et al. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res. 2008;5:5966.
  • 19
    Yanai H, Tomono Y, Ito K, et al. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J. 2008;7:710.
  • 20
    Duvnjak L, Bulum T, Metelko Ž. Hypertension and the metabolic syndrome. Diabetol Croat. 2008;37:8389.
  • 21
    Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol. 2003;35:807825.
  • 22
    Rossi G, Belfiore A, Bernini G, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008;93:25662571.
  • 23
    Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144(6):21952200.
  • 24
    Waki H, Tontonoz P. Endocrine functions of adipose tissue. Annu Rev Pathol. 2007;2:3156.
  • 25
    Cassis L, Police S, Yiannikouris F, et al. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep. 2008;10:9398.
  • 26
    Guilherme A, Virbasius J, Puri V, et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:367377.
  • 27
    Hsueh W, Tangirala R. Adiponectin. In: IzzoJ, HRB, eds. Hypertension Primer, 4th edn. Philadelphia, PA: Lippincott Williams and Wilkins; 2008:113115.
  • 28
    Yamauchi T, Kamon J, Waki H, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278:24612468.
  • 29
    Chow W, Cheung B, Tso A, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertens Pregnancy. 2007;49:14551461.
  • 30
    Pischon T, Girman C, Rifai N, et al. Association between dietary factors and plasma adiponectin concentrations in men. Am J Clin Nutr. 2005;81:780786.
  • 31
    Suganami T, Nishida J, Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol. 2005;25:20622068.
  • 32
    Doughan A, Harrison D, Dikalov S. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488496.
  • 33
    Solinas G, Vilcu C, Neels J, et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 2007;6:386397.
  • 34
    Hevener A, Olefsky J, Reichart D, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest. 2007;117:16581669.
  • 35
    Schenk S, Saberi M, Olefsky J. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008;118:29923002.
  • 36
    Patsouris D, Li P, Thapar D, et al. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008;8:301309.
  • 37
    Muoio D, Newgard C. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9:193205.
  • 38
    Petersen K, Dufour S, Shulman G. Decreased insulin-stimulated ATP synthesis and phosphate transport in muscle of insulin-resistant offspring of type 2 diabetic parents. PLoS Med. 2005;2:e233.
  • 39
    Hsueh WA, Orloski L, Wyne K. Prediabetes: the importance of early identification and intervention. Postgrad Med. 2010;122(4):129143.
  • 40
    Turkish A. Nonalcoholic fatty liver disease: emerging mechanisms and consequences. Curr Opin Clin Nutr Metab Care. 2008;11:128133.
  • 41
    Schwimmer J, Deutsch R, Kahen T, et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:13881393.
  • 42
    McGavock J, Victor R, Unger R, et al. Adiposity of the heart, revisited. Ann Intern Med. 2006;144:517524.
  • 43
    Schorr U, Blaschke K, Turan S, et al. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens. 1998;16:14751480.
  • 44
    Yvan-Charvet L, Massiéra F, Lamande N, et al. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue. Endocrinol Metab Clin North Am. 2009;150:14211428.
  • 45
    Kurukulasuriya LR, Stas S, Lastra G, et al. Hypertension in obesity. Endocrinol Metab Clin North Am. 2008;37(3):647662, ix.
  • 46
    Nagel JM, Tietz AB, Goke B, et al. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism. 2006;55(9):11491154.
  • 47
    Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens. 2005;23(3):463473.
  • 48
    Engeli S, Boschmann M, Frings P, et al. Influence of salt intake on renin-angiotensin and natriuretic peptide system genes in human adipose tissue. Hypertension. 2006;48(6):11031108.
  • 49
    Scheen A. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs. 2004;64:25372565.
  • 50
    Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145153.
  • 51
    Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2002;20(9):18791886.
  • 52
    Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):29812997.
  • 53
    Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003;21(8):15631574.
  • 54
    Vermes E, Ducharme A, Bourassa MG, et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 2003;107(9):12911296.
  • 55
    Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003;362(9386):759766.
  • 56
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):20222031.
  • 57
    Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 2004;30(6):498505.
  • 58
    Gillespie EL, White CM, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care. 2005;28(9):22612266.
  • 59
    Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128(12 Pt 1):982988.
  • 60
    Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):14561462.
  • 61
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851860.
  • 62
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861869.
  • 63
    Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870878.
  • 64
    Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355(15):15511562.
  • 65
    Zappe DH, Sowers JR, Hsueh WA, et al. Metabolic and antihypertensive effects of combined angiotensin receptor blocker and diuretic therapy in prediabetic hypertensive patients with the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2008;10(12):894903.
  • 66
    Cooper ME. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am J Hypertens. 2004;17(11 Pt 2):16S20S; quiz A2–4.
  • 67
    Vijayaraghavan K, Deedwania PC. The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiol Clin. 2005;23(2):165183.
  • 68
    Segura J, Ruilope LM. Obesity, essential hypertension and renin-angiotensin system. Public Health Nutr. 2007;10(10A):11511155.
  • 69
    Sharma AM, Engeli S. The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1(1):2935.
  • 70
    Sowers JR, Stump CS. Insights into the biology of diabetic vascular disease: what’s new? Am J Hypertens. 2004;17(11 Pt 2):2S6S; quiz A2–4.
  • 71
    Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004;30(6):487496.
  • 72
    Holman RR, Haffner SM, McMurray JJ, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):14631476.
  • 73
    Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709717.
  • 74
    Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217(1–2):5358.
  • 75
    Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib Nephrol. 2006;151:122134.
  • 76
    Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356362.
  • 77
    Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837853.
  • 78
    Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):15771589.
  • 79
    Susztak K, Raff AC, Schiffer M, et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225233.
  • 80
    Durvasula RV, Shankland SJ. Activation of a local renin angiotensin system in podocytes by glucose. Am J Physiol Renal Physiol. 2008;294(4):F830F839.
  • 81
    Lennon R, Pons D, Sabin MA, et al. Saturated fatty acids induce insulin resistance in human podocytes: implications for diabetic nephropathy. Nephrol Dial Transplant. 2009;24(11):32883296.
  • 82
    Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118(5):16451656.
  • 83
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977986.
  • 84
    Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994;271(4):275279.
  • 85
    Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med. 1995;99(5):497504.
  • 86
    Brichard SM, Santoni JP, Thomas JR, et al. Long term reduction of microalbuminuria after 1 year of angiotensin converting enzyme inhibition by perindopril in hypertensive insulin-treated diabetic patients. Diabetes Metab. 1990;16(1):3036.
  • 87
    Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349(9068):17871792.
  • 88
    Mann JF, Gerstein HC, Yi QL, et al. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis. 2003;42(5):936942.
  • 89
    Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med. 2009;151(1):110, W1–2.
  • 90
    Bakris G, Burgess E, Weir M, et al. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 2008;74(3):364369.
  • 91
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):17551762.
  • 92
    Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):15751585.
  • 93
    Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829840.
  • 94
    Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547553.
  • 95
    Beulens JW, Patel A, Vingerling JR, et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia. 2009;52(10):20272036.
  • 96
    Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme. Eye. 2009;24(1):16.
  • 97
    Klein R, Zinman B, Gardiner R, et al. The relationship of diabetic retinopathy to preclinical diabetic glomerulopathy lesions in type 1 diabetic patients. Diabetes. 2005;54(2):527533.
  • 98
    Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233244.
  • 99
    Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):13941402.
  • 100
    Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):4051.
  • 101
    Wilkinson-Berka JL, Tan G, Jaworski K, et al. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res. 2009;104(1):124133.
  • 102
    Higuchi A, Ohashi K, Kihara S, et al. Adiponectin suppresses pathological microvessel formation in retina through modulation of tumor necrosis factor-alpha expression. Circ Res. 2009;104(9):10581065.
  • 103
    Higuchi A, Ohashi K, Shibata R, et al. Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism. Arterioscler Thromb Vasc Biol. 2010;30(1):4653.
  • 104
    Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation. Diabetologia. 2001;44(9):11181120.
  • 105
    Baruch L, Anand I, Cohen IS, et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation. 1999;99(20):26582664.
  • 106
    Stein M, Boulaksil M, Jansen JA, et al. Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol. 2010;299(2):H310H321.
  • 107
    Kai H, Kuwahara F, Tokuda K, et al. Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res. 2005;28(6):483490.
  • 108
    Dzau VJ. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med. 1993;153(8):937942.
  • 109
    Chinnaiyan KM, Alexander D, McCullough PA. Role of angiotensin II in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich). 2005;7(12):740747.
  • 110
    Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42(6):11371143.
  • 111
    Alberti G, Zimmet P, Shaw J, et al. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: International Diabetes Federation; 2006.
  • 112
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469480.
  • 113
    Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):27352752.